Many previous clinical studies have confirmed a better tumor response and survival of receiving PD-1/PD-1 inhibitors plus chemotherapy than standard chemotherapy in patients with non-small cell lung cancer (18), breast cancer (19), esophagus cancer (20), and biliary tract cancer (11). Here, PDCD1 is linked to non-small cell lung carcinoma.